- Home
- FTDR vs PTCT Comparison
FTDR vs PTCT Comparison
Compare FTDR & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FTDR | PTCT |
|---|---|---|
| Founded | 1971 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 5.3B |
| IPO Year | 2018 | 2013 |
Fundamental Metrics
Financial Performance| Metric | FTDR | PTCT |
|---|---|---|
| Price | $52.87 | $78.49 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 17 |
| Target Price | $59.75 | ★ $73.76 |
| AVG Volume (30 Days) | 791.8K | ★ 2.3M |
| Earning Date | 11-05-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 15.41 | N/A |
| EPS | 3.46 | ★ 8.94 |
| Revenue | ★ $2,042,000,000.00 | $1,779,150,000.00 |
| Revenue This Year | $14.60 | $119.02 |
| Revenue Next Year | $6.58 | N/A |
| P/E Ratio | $15.25 | ★ $8.78 |
| Revenue Growth | 11.77 | ★ 97.54 |
| 52 Week Low | $35.61 | $35.95 |
| 52 Week High | $70.14 | $87.50 |
Technical Indicators
Market Signals| Indicator | FTDR | PTCT |
|---|---|---|
| Relative Strength Index (RSI) | 41.05 | 58.39 |
| Support Level | $52.97 | $75.34 |
| Resistance Level | $55.00 | $87.50 |
| Average True Range (ATR) | 1.47 | 3.01 |
| MACD | 0.75 | 0.05 |
| Stochastic Oscillator | 69.02 | 37.82 |
Price Performance
Historical ComparisonAbout FTDR Frontdoor Inc.
Frontdoor Inc is a United States-based company that provides home service plans. It owns multiple home service brands including American Home Shield, HSA, OneGuard, and Landmark brands. Through its home service plans, the company helps its customers maintain their homes and protect against costly and unexpected breakdowns of essential home systems and appliances.
About PTCT PTC Therapeutics Inc.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.